XORTX Therapeutics (XRTX) investor relations material

Company overview and business model

• Focuses on developing and commercializing therapies for diseases linked to aberrant purine and uric acid metabolism, targeting gout, autosomal dominant polycystic kidney disease (ADPKD), type 2 diabetic nephropathy (T2DN), and acute kidney injury (AKI) associated with respiratory virus infection.

• Pipeline includes four programs: XRx-026 (gout), XRx-008 (ADPKD), XRx-101 (AKI), and XRx-225 (T2DN), with XRx-026 prioritized for near-term marketing approval and revenue generation.

• Employs a pipeline-in-a-product strategy, leveraging proprietary oxypurinol formulations and intellectual property to address unmet medical needs in renal and metabolic diseases.

• Holds exclusive patents in the US and Europe for uric acid lowering agents and proprietary xanthine oxidase inhibitor formulations.

Financial performance and metrics

• Reported operating losses and negative operating cash flow for the fiscal years ended December 31, 2024 and 2023.

• As of September 30, 2025, pro forma as adjusted cash position would be $6.95 million and total capitalization $8.92 million after the offering.

• Net tangible book value per share after the offering would be approximately $0.39, with immediate dilution of $0.01 per share to new investors.

Use of proceeds and capital allocation

• Expects to receive approximately $4.3 million in net proceeds from the offering, assuming no sale of Pre-Funded Warrants and no exercise of Warrants.

• Proceeds will be used to fund ongoing research and development activities, working capital, and general corporate purposes, with management retaining broad discretion over allocation.